Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells

The combination of metformin and TKIs for non-small cell lung cancer has been proposed as a strategy to overcome resistance of neoplastic cells induced by several molecular mechanisms. This study sought to investigate the effects of a second generation TKI afatinib, metformin, or their combination o...

Full description

Bibliographic Details
Main Authors: Pedro Barrios-Bernal, Norma Hernandez-Pedro, Mario Orozco-Morales, Rubí Viedma-Rodríguez, José Lucio-Lozada, Federico Avila-Moreno, Andrés F. Cardona, Rafael Rosell, Oscar Arrieta
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceuticals
Subjects:
lung cancer
afatinib–metformin
EGFR
glycolysis
oxidative phosphorylation
epithelial–mesenchymal transition
Online Access:https://www.mdpi.com/1424-8247/15/3/381

Internet

https://www.mdpi.com/1424-8247/15/3/381

Similar Items